We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .
[Evaluation of cicletanine efficiency and tolerance in hypertensive patients treated with beta-blockaders].
Efficacy and tolerance of cicletanine , the first derivative of furopyridines have been studied in a 3 parallel groups double blind study ; 120 essential mild hypertensive patients uncontrolled by beta blocking therapy were included . After a period of one month during which a treatment by placebo was added to beta blocking therapy , the patients were r and omly allocated into 3 groups : group I ( placebo : 40 patients ) , group II ( cicletanine 50 mg/d : 41 patients ) , group III ( cicletanine 100 mg/d : 39 patients ) . Eight patients were withdrawn in the group I ( poor efficacy , n = 5 or unexpected event , n = 3 ) , and one in the group III ( unexpected event ) . At the beginning of the treatment period ( DO ) , lying blood pressure ( LBP ) was respectively for groups I , II and III 171 + /- 14/104 + /- 6 , 174 + /- 13/104 + /- 5 , 172 + /- 15/105 + /- 6 mmHg . 171 + /- 14/104 + /- 6 , 174 + /- 13/104 + /- 5 , 172 + /- 15/105 + /- 6 mmHg . After 3 months of treatment LBP was respectively 168 + /- 21/97 + /- 10 , 151 + /- 12/85 + /- 7 , 147 + /- 14/82 + /- 9 mmHg . A significant treatment effect ( p less than 0.001 ) was observed on SBP with groups II and III only , and on DBP with the 3 groups . This lowering effect was comparable in groups II and III , and greater ( p less than 0.001 ) in these groups than in group I. At the end of this study the percentage of patients whose BP was normalized was respectively for groups I , II and III : 5 p. 100 , 51 p. 100 and 74 p. 100 . Clinical and biological tolerance were good . ( ABSTRACT TRUNCATED AT 250 WORDS
We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .